Cancer Research Institute
Clinical Trials
A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
This study is currently enrolling.
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced ...
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
This study is currently enrolling.
Objectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the preliminary antitumor activity of N ...
A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
This study is currently enrolling.
This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection in Patients with Relapsed/Refractory Hematologic Malignancies
This study is currently enrolling.
The purpose of this research study is to test the safety of PRT1419 at different dose levels to find out what effects, good and/or bad, PRT1419 has on you and your type of cancer. The information collected from you and from oth ...
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer
This study is currently enrolling.
The purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular NSCLC and breast cancer. ...
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer
This study is currently enrolling.
Participants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 negative (HER2)-negative breast cancer and have ...
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression
This study is currently enrolling.
You are being asked to take part in Part 2 of this study because you have advanced gastric cancer (a disease in which cancer cells form in the lining of the stomach) or gastroesophageal junction cancer (a type of cancer forming ...
A Phase 2 Study of INotuzumab Ozogamicin (NSC# 772518, IND #133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
This study is currently enrolling.
The overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory B-ALL.
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In
Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade
Serous Ovarian Cancer (LGSOC).
Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade
Serous Ovarian Cancer (LGSOC).
This study is currently enrolling.
The main aims of this clinical study are to: (a) Find out if the best course of study treatment is to take either VS-6766 alone (monotherapy) or to take VS-6766 together (in combination) with defactinib; (b) Understand the safe ...